ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
주요 하이라이트
2023년, 미국은 7대 시장 내 비만 저혈당증 시장 규모의 약 90%를 차지했습니다.
비만 저혈당증은 위 우회술, 슬리브형 위 절제술 등의 비만 저혈당증이 발생하는 것을 말합니다. 일반적으로 수술 후 몇년이내에 발생합니다.
급격한 체중 감소, 소화관 해부학적 구조의 변화, 인슐린 감수성 증가, 고인슐린혈증, 반응성 저혈당 등 여러 가지 위험 요인이 비만 후 저혈당의 원인이 될 수 있습니다.
2023년 주요 7개국에서 비만 저혈당증(PBH) 환자 수는 약 10만 명으로 집계됐습니다. 주요 7개국 중 미국이 가장 많은 환자 수를 기록했고, 프랑스가 그 뒤를 이었습니다.
비만 저혈당증은 급격한 체중 감소, 소화관 해부학적 구조의 변화, 인슐린 감수성 증가, 고인슐린혈증, 반응성 저혈당증 등 여러 가지 위험 요인이 관련되어 있습니다.
비만 수술은 고도비만에 대한 가장 효과적인 치료법으로 입증되었으며, 비만도 및 비만 관련 동반 질환을 유의하게 개선하는 것으로 나타났습니다. 미국에서는 매년 비만 수술 건수가 증가하고 있으며, 비만 수술 환자에서 저혈당 증상의 수술 후 유병률도 증가하고 있습니다.
비만 저혈당증의 병태생리는 복잡하며, 여러 가지 상호 연관된 기전이 관련되어 있습니다. 저혈당은 비만 수술 후 음식물 섭취에 대한 정상적인 호르몬 및 대사 반응의 변화에 기인하는 것으로 예상됩니다.
비만 저혈당증의 진단은 임상 평가, 병력 청취, 혈당 모니터링 및 저혈당의 다른 잠재적 원인을 배제하는 조합이 필요합니다. 진단을 보조하기 위해 혼합식 부하 검사, 연속 혈당 모니터링, 췌장 영상 진단과 같은 추가 검사가 이용됩니다.
비만 저혈당증의 관리에는 소량씩 자주 식사하기, 고혈당 지수 음식 피하기, 단순당 제한과 같은 식이 조절이 포함됩니다. 비만 저혈당증은 혈당 조절을 위해 아카보스, 디아조사이드, 글루카곤 유사 펩타이드-1(GLP-1) 수용체 작용제와 같은 약물이 처방될 수 있습니다. 심한 경우에는 비만 수술의 부분적 또는 완전한 취소와 같은 외과적 개입이 고려될 수 있습니다.
현재 비만 저혈당증 치료제로 FDA 승인을 받은 치료제는 없습니다. 그러나 비만 저혈당증 치료제로 연구되고 있는 것은 많지 않은 상황입니다.
개발에 참여하고 있는 주요 비만 저혈당증 관련 기업은 Vogenx(mizagliflozin)와 Eiger BioPharmaceuticals(avexitide)가 있습니다.
2024년 4월, Vogenx는 비만 수술 후 저혈당 진단을 받은 환자를 대상으로 미자글리플로진을 평가하기 위한 임상 2상 시험 VGX-001-012의 마지막 환자 투여를 완료했다고 발표했습니다.
비만 저혈당증 시장 보고서 요약
이 보고서는 역학 부문과 예측에 대한 광범위한 지식을 제공하고, 진단율, 질병 진행, 치료 가이드라인의 미래 잠재적 성장에 대한 깊은 이해를 제시합니다. 이러한 측면에 대한 종합적인 통찰력을 제공하여 주제에 대한 철저한 평가를 가능하게 합니다.
또한, 현재의 관리 기술과 새로운 치료법에 대한 종합적인 설명과 현재 치료 상황에 영향을 미치고 전반적인 시장 변화에 영향을 미칠 수 있는 중기(Phase II) 및 주목할 만한 치료법에 대한 상세한 프로파일이 이 보고서에서 제공됩니다.
또한 질병에 대한 종합적인 분석을 포함하며, 비만 저혈당증 시장 규모(2020-2034년)의 과거와 예측에 대한 상세한 검토를 제공합니다. 또한, 치료법 시장 점유율, 상세한 전제조건, 연구 방법론의 근거도 포함되어 있습니다. 이 비만 저혈당증 시장 보고서에는 주요 7개국에 대한 약물 아웃리치도 포함되어 있습니다.
비만 저혈당증 시장 보고서는 주요 7개국의 비만 저혈당증 시장 형성 및 추진에 도움이 되는 SWOT 분석과 다양한 병원 및 유명 대학의 전문가를 포함한 전문가 통찰력/KOL의 견해, 환자 여정, 치료 선호도를 통해 동향을 이해하고 사업 전략을 수립하는 데 도움이 되는 질적 통찰력을 제공합니다. 포함하고 있습니다.
비만 저혈당증은 roux-en-Y 위 우회술(RYGB) 및 수직 슬리브 위 절제술(SG) 후 발생하는 비만 수술의 합병증으로 인식되고 있습니다. 반응성 저혈당증 및 후기 덤핑 증후군으로도 알려진 비만 저혈당증은 식후 포도당 농도의 급격한 상승이 인슐린의 고분비를 자극하여 저혈당을 유발하는 대사성 합병증입니다.
비만 저혈당증의 진단은 임상 평가, 병력 청취, 혈당 모니터링, 저혈당의 다른 잠재적 원인 배제 등의 조합이 필요합니다. 진단을 돕기 위해 혼합 식이 부하 검사, 연속 혈당 모니터링, 췌장 영상 진단과 같은 추가 검사가 이용됩니다.
아칼보스가 1차 치료제로 사용되고 있지만, 소화기 부작용으로 인해 이 치료법이 제한되어 있습니다. 디아조사이드와 옥트레오타이드도 사용되어 왔으나, 부작용과 환자의 비복용성으로 인해 그 유용성이 제한되어 왔으며, 그 결과는 다양합니다. 흥미롭게도 외인성 GLP-1 수용체 작용제는 PBH의 개선 효과를 나타냅니다. 아마도 저혈당 상태에서 B세포의 인슐린 분비를 억제하고 A세포의 글루카곤 분비를 증가시킴으로써 저혈당 상태를 개선하는 것으로 추정됩니다. 역사적으로 위루술, 위 우회술, 췌장 원위부 절제술이 외과적 치료로 권장되어 왔으며, CCB, 니페디핀 또는 벨라파밀을 사용하여 영양요법과 외과적 치료 사이의 치료 간극을 메우는 것이 가치가 있습니다.
2023년 주요 7개국에서 비만 저혈당증 환자 수는 약 11만 명으로 추정되며, 2034년까지 증가할 것으로 예상됩니다.
2023년에는 미국이 비만 수술 후 저혈당 사례의 약 80%를 차지해 가장 많았습니다.
2023년, 미국에서는 슬리브형 위절제술의 경우 비만 후 저혈당증이 가장 많았고, 그 다음이 Roux-en-Y 위우회술, 그 다음이 기타 사례였습니다.
비만 후 저혈당증의 중증도에 대해 미국에서는 2023년 경증에서 중등도 범주에 속하는 경우가 90% 이상이었습니다.
미국에서는 2023년 비만 저혈당증 치료 사례가 5만 건에 육박했습니다.
비만 수술 후 저혈당 시장
Vogenx, Eiger BioPharmaceuticals 등 다양한 주요 기업들이 비만 저혈당증(PBH)의 치료 현황을 주도하고 있습니다. 국가별 및 치료법별 시장 규모는 다음과 같습니다.
2023년 주요 7개국에서 비만 저혈당증 시장 규모는 약 2억 달러로, 비만 저혈당증 사례 증가와 새로운 치료법 출시로 인해 2034년까지 증가할 것으로 예측됩니다.
주요 7개국 중 2023년 비만 저혈당증 시장 규모는 미국이 가장 컸으며, 프랑스, 이탈리아가 그 뒤를 이을 것으로 예상됩니다.
신흥 치료제 중 Eiger BioPharmaceuticals의 AVEXITIDE가 예측 기간(2024-2034년) 동안 가장 높은 비만 저혈당증 시장 규모를 차지할 것으로 예상됩니다.
세계 주요 7개국의 비만 저혈당증(비만 저혈당증) 시장에 대해 조사했으며, 시장 개요, 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 미충족 의료 수요 등을 정리하여 전해드립니다.
In 2023, the United States accounted for approximately 90% of the total Post-Bariatric hypoglycemia market size within the seven major markets.
Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleeve gastrectomy. It typically occurs within a few years after surgery.
Several risk factors contribute to Post-Bariatric hypoglycemia, including rapid weight loss, altered gastrointestinal anatomy, increased insulin sensitivity, hyperinsulinemia, and reactive hypoglycemia.
In 2023, there were approximately 100,000 cases of Post-Bariatric hypoglycemia (PBH) Cases in the 7MM. Among the 7MM, the United States accounted for the highest number of cases, which was followed by France.
Several risk factors contribute to Post-Bariatric hypoglycemia, including rapid weight loss, altered gastrointestinal anatomy, increased insulin sensitivity, hyperinsulinemia, and reactive hypoglycemia.
Bariatric surgery has proven to be the most effective treatment for severe obesity, leading to significant improvements in body mass index and obesity-related co-morbidities. With increasing bariatric surgery procedures performed per year in the United States, postoperative prevalence of hypoglycemia symptoms in bariatric surgery patients is also increasing.
The pathophysiology of Post-Bariatric hypoglycemia is complex and involves several inter-related mechanisms. It is believed to result from alterations in the normal hormonal and metabolic response to food intake following bariatric surgery.
Diagnosis of Post-Bariatric hypoglycemia involves a combination of clinical evaluation, medical history review, blood glucose monitoring, and ruling out other potential causes of hypoglycemia. Additional tests such as mixed meal tolerance tests, continuous glucose monitoring, and pancreatic imaging may be utilized to aid in diagnosis.
The management of Post-Bariatric hypoglycemia involves dietary modifications, such as consuming small and frequent meals, avoiding high-glycemic index foods, and restricting simple sugars. Post-Bariatric hypoglycemia Medications, including acarbose, diazoxide, or glucagon-like peptide-1 (GLP-1) receptor agonists, may be prescribed to help control blood sugar levels. In severe cases, surgical interventions, such as partial or complete reversal of the bariatric surgery, may be considered.
There are currently no therapeutics approved by the FDA for the treatment of Post-Bariatric hypoglycemia. However, few therapies are being investigated for the treatment of Post-Bariatric hypoglycemia.
Some key Post-Bariatric hypoglycemia companies involved in the development are Vogenx (mizagliflozin) and Eiger BioPharmaceuticals (avexitide).
In April 2024, Vogenx announced that it has completed dosing of the last patient in its Phase II clinical study VGX-001-012 evaluating mizagliflozin in patients diagnosed with post-bariatric hypoglycemia.
Post-Bariatric hypoglycemia Market Report Summary
The Post-Bariatric hypoglycemia market report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of mid-stage (Phase II) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
The Post-Bariatric hypoglycemia market report also encompasses a comprehensive analysis of the disease, providing an in-depth examination of its historical and projected Post-Bariatric hypoglycemia market size (2020-2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The Post-Bariatric hypoglycemia market report also includes drug outreach coverage in the 7MM region.
The Post-Bariatric hypoglycemia market report includes qualitative insights that provide an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM Post-Bariatric hypoglycemia market.
The table given below further depicts the key segments provided in the report:
Post-Bariatric hypoglycemia Treatment Market
Post-Bariatric hypoglycemia Overview
Post-Bariatric hypoglycemia is an increasingly recognized complication of bariatric surgery, occurring after roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (SG). Postbariatric surgery hypoglycemia, also known as reactive hypoglycemia and late dumping syndrome, is a metabolic complication in which a spike in glucose levels after eating a meal stimulates a high insulin secretion, leading to low blood sugar.
Post-Bariatric hypoglycemia Diagnosis
Diagnosis of Post-Bariatric hypoglycemia involves a combination of clinical evaluation, medical history review, blood glucose monitoring, and ruling out other potential causes of hypoglycemia. Additional tests such as mixed meal tolerance tests, continuous glucose monitoring, and pancreatic imaging may be utilized to aid in diagnosis.
Post-Bariatric hypoglycemia Treatment
Acarbose has been used as first-line treatment, although adverse gastrointestinal symptoms limit this option. Diazoxide and octreotide have been used with mixed results, but side effects and patient nonadherence limit their utility. Interestingly, exogenous GLP-1 receptor agonists have also demonstrated improvement in PBH, possibly through downregulation of insulin secretion from B-cells and increased secretion of glucagon from a-cells during conditions of hypoglycemia. Historically, surgical treatments were recommended more commonly, gastrostomy tube placement, reversal of gastric bypass anatomy, and distal pancreatectomy. It is worth using CCBs, nifedipine, or verapamil to bridge the treatment gap between nutrition and surgical therapy.
Post-Bariatric hypoglycemia Epidemiology
The Post-Bariatric hypoglycemia epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Type-specific Bariatric Surgery Cases, Total Post-Bariatric hypoglycemia Cases, Post-Bariatric hypoglycemia Cases in types of Bariatric Surgeries, Severity-specific Post-Bariatric hypoglycemia Cases, and Total Treated cases of Post-Bariatric hypoglycemia in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
In 2023, the total Post-Bariatric hypoglycemia cases in the 7MM were estimated to be approximately 110,000 cases which, as per DelveInsight's estimates, will increase by 2034.
In 2023, the US accounted for the highest cases of Post-Bariatric hypoglycemia with approximately 80% cases.
As per DelveInsight's analysis, in 2023, there were higher cases of Post-Bariatric hypoglycemia in sleeve gastrectomy cases, which was followed by Roux-en-Y gastric bypass cases, and cases in others in the US.
As per severity of Post-Bariatric hypoglycemia, there were more than 90% cases in the mild to moderate category in 2023, in the United States.
There were nearly 50,000 treated cases of Post-Bariatric hypoglycemia in 2023 in the United States.
Post-Bariatric hypoglycemia Market
Various key players are leading the treatment landscape of Post-Bariatric hypoglycemia (PBH), such as Vogenx, Eiger BioPharmaceuticals, and others. The details of the country-wise and therapy-wise market size have been provided below.
In 2023, the Post-Bariatric hypoglycemia market size in the 7MM was nearly 200 USD million and it is expected to increase by 2034, driven by an increase in the cases of Post-Bariatric hypoglycemia and the launch of new therapies.
Among the 7MM, the United States accounted for the highest Post-Bariatric hypoglycemia market size, followed by France and Italy, in 2023.
Among the emerging therapies, Eiger BioPharmaceuticals' AVEXITIDE is expected to garner the highest Post-Bariatric hypoglycemia market size during the forecast period (2024-2034).
Post-Bariatric hypoglycemia Drug Chapters
The section dedicated to drugs in the Post-Bariatric hypoglycemia market report provides an in-depth evaluation of mid-stage pipeline drugs (Phase II) related to Post-Bariatric hypoglycemia.
The drug chapters section provides valuable information on various aspects related to clinical trials of Post-Bariatric hypoglycemia, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Post-Bariatric hypoglycemia.
Post-Bariatric hypoglycemia Emerging Therapies
Mizagliflozin: Vogenx
Mizagliflozin follows an oral route of administration and minimally absorb the inhibitor of Sodium-glucose transporter 1 (SGLT1). Post-Bariatric hypoglycemia patients have elevated SGLT1 levels in the gut. This elevated blood glucose stimulates uncontrolled insulin secretion in Post-Bariatric hypoglycemia patients. In February 2024, Vogenx announced completion of patient enrollment of a mid-Phase II clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients diagnosed with post-bariatric hypoglycemia.
AVEXITIDE (exendin 9-39) is a 31-amino acid peptide that selectively targets and blocks GLP-1 receptors, reducing dysregulated insulin secretion by the pancreas and reducing fasting and postprandial hypoglycemia. In June 2023, the company announced that the US FDA has granted breakthrough therapy designation to AVEXITIDE for the treatment of Post-Bariatric hypoglycemia.
Note: Detailed assessment will be provided in the final report of Post-Bariatric hypoglycemia...
Post-Bariatric hypoglycemia Market Outlook
Most of the therapies are based on case series or reports and extrapolated from their use in other conditions that cause hypoglycemia. Acarbose has been used as first-line treatment, although adverse gastrointestinal symptoms limit this option. Diazoxide and octreotide have been used with mixed results, but side effects and patient nonadherence limit their utility. Interestingly, exogenous GLP-1 receptor agonists have also demonstrated improvement in PBH, possibly through down regulation of insulin secretion from B-cells and increased secretion of glucagon from a-cells during conditions of hypoglycemia.
Several drugs are being investigated to treat Post-Bariatric hypoglycemia, including mizagliflozin and exendin 9-39. Both drugs have demonstrated significant improvements in PBH patients with well-tolerated safety profiles.
As no approved therapies are available in the Post-Bariatric hypoglycemia market, there is a huge opportunity for pharmaceutical firms to develop targeted and effective therapies for treating Post-Bariatric hypoglycemia.
Post-Bariatric hypoglycemia KOL Views
To stay abreast of the latest trends in the Post-Bariatric hypoglycemia market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.
We have reached out to industry experts to gather insights on various aspects of Post-Bariatric hypoglycemia, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.
Our team of analysts at Delveinsight connected with more than 10 KOLs across the 7MM. We contacted institutions such as the King's College London, University of Valencia, Arden University, Stanford University, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Post-Bariatric hypoglycemia market, which will assist our clients in analyzing the overall epidemiology and market scenario.
The opinion of experts from various regions has been provided below:
Post-Bariatric hypoglycemia Qualitative Analysis
We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging Post-Bariatric hypoglycemia therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Post-Bariatric hypoglycemia, one of the most important primary endpoints was change from baseline mean glucose nadir. Based on these, the overall efficacy is evaluated.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Post-Bariatric hypoglycemia Market Access and Reimbursement
Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.
The Post-Bariatric hypoglycemia market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Would there be any changes observed in the current treatment approach?
Will there be any improvements in Post-Bariatric hypoglycemia management recommendations?
Would research and development advances pave the way for future tests and therapies for Post-Bariatric hypoglycemia?
Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Post-Bariatric hypoglycemia?
What kind of uptake will the new therapies witness in coming years in Post-Bariatric hypoglycemia patients and what is the expected launch date of AVEXITIDE?
Table of Contents
1. Key Insights
2. Report Introduction
3. Postbariatric Hypoglycemia (PBH) Market Overview at a Glance
3.1. Market Share (%) Distribution of Postbariatric Hypoglycemia (PBH) by Countries in 2020
3.2. Market Share (%) Distribution of Postbariatric Hypoglycemia (PBH) by Countries in 2034
3.3. Market Share (%) Distribution by Class of Postbariatric Hypoglycemia (PBH) Therapies in 2020
3.4. Market Share (%) Distribution by Class of Postbariatric Hypoglycemia (PBH) Therapies in 2034
4. Executive Summary of Postbariatric Hypoglycemia
5. Disease Background and Overview
5.1. Introduction
5.2. Hypoglycemia After Gastric Bypass Surgery
5.3. Etiology of PBH
5.4. Risk Factors for Hypoglycemia
5.5. Pathophysiology of PBH
5.6. Diagnostic Evaluation
5.7. Differential Diagnosis
5.8. Diagnostic Guidelines
6. Methodology
7. Post-Bariatric hypoglycemia Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Postbariatric Hypoglycemia (PBH) Cases in the 7MM
7.4. The United States
7.4.1. Type-specific Bariatric Surgery Cases in the United States
7.4.2. Total Postbariatric Hypoglycemia (PBH) Cases in the United States
7.4.3. Postbariatric Hypoglycemia (PBH) Cases in types of Bariatric Surgeries in the United States
7.4.4. Severity-specific Postbariatric Hypoglycemia (PBH) Cases in the United States
7.4.5. Total Treated cases of Postbariatric Hypoglycemia (PBH) in the United States
7.5. EU4 and the UK
7.5.1. Type-specific Bariatric Surgery Cases in EU4 and the UK
7.5.2. Total Postbariatric Hypoglycemia (PBH) Cases in EU4 and the UK
7.5.3. Postbariatric Hypoglycemia (PBH) Cases in Types of Bariatric Surgeries in EU4 and the UK
7.5.4. Severity-specific Postbariatric Hypoglycemia (PBH) Cases in EU4 and the UK
7.5.5. Total Treated Cases of Postbariatric Hypoglycemia (PBH) in EU4 and the UK
7.6. Japan
7.6.1. Type-specific Bariatric Surgery Cases in Japan
7.6.2. Total Postbariatric Hypoglycemia (PBH) Cases in Japan
7.6.3. Postbariatric Hypoglycemia (PBH) Cases in types of Bariatric Surgeries in Japan
7.6.4. Severity-specific Postbariatric Hypoglycemia (PBH) Cases in Japan
7.6.5. Total Treated cases of Postbariatric Hypoglycemia (PBH) in Japan
